Drug profile · INN
capecitabine
CAPECITABINE SANDOZ
capecitabine (CAPECITABINE SANDOZ) is a thymidylate synthase inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — capecitabine
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 2
- Programs
- 105
- Data quality
- 0.89
Quick answer
capecitabine (CAPECITABINE SANDOZ) is a thymidylate synthase inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Thymidylate synthase inhibitor
Primary target: DNA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is capecitabine?
capecitabine (CAPECITABINE SANDOZ) is a thymidylate synthase inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for capecitabine?
CAPECITABINE SANDOZ is a marketed brand name for capecitabine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of capecitabine?
capecitabine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.